ReviewTherapeutic advances in cardiovascular disease
Intravenous antiplatelet therapies (glycoprotein IIb/IIIa receptor inhibitors and cangrelor) in percutaneous coronary intervention: from pharmacology to indications for clinical use.
Review in Therapeutic advances in cardiovascular disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 75 citations in OpenAlex.
- Intracoronary adjunctive therapies for ST-elevation myocardial infarction: a network meta-analysis of trials.European heart journal. Cardiovascular pharmacotherapy · 2026Pooled it
- Interaction of Intraprocedural Antiplatelets and Intravenous Thrombolysis in Acute Intracranial Stenting: RESISTANT Registry Subanalysis.Annals of clinical and translational neurology · 2026Article
- Comprehensive Review of Antiplatelet Therapy in Secondary Prevention of Myocardial Infarction: Mechanisms, Clinical Evidence, and Future Directions.Cardiovascular therapeutics · 2026Review
- Timing, indications and transition patterns associated with cangrelor use in patients undergoing PCI.Journal of thrombosis and thrombolysis · 2026Article
- Pharmacological and Interventional Prevention and Treatment of Microvascular Obstruction Following Primary PCI in STEMI.Journal of cardiovascular development and disease · 2025Review
- Platelets in Thrombosis and Atherosclerosis: A Double-Edged Sword.The American journal of pathology · 2024Review
- Coronary microvascular obstruction and dysfunction in patients with acute myocardial infarction.Nature reviews. Cardiology · 2024Review
- Prehospital treatment with zalunfiban (RUC-4) in patients with ST- elevation myocardial infarction undergoing primary percutaneous coronary intervention: Rationale and design of the CELEBRATE trial.American heart journal · 2023Article
- Personalized Approaches to Antiplatelet Treatment for Cardiovascular Diseases: An Umbrella Review.Pharmacogenomics and personalized medicine · 2023Review
- Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: A Position Paper from the ESC Working Group on Thrombosis, in collaboration with the European Heart Rhythm Association, the Association for Acute CardioVascular Care and the Asia-Pacific Heart Rhythm Society.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2022Article
- Current Status and Future Direction of Antithrombotic Therapy for Patients with STEMI Undergoing Primary PCI.Reviews in cardiovascular medicine · 2022Review
- Anticoagulation and Antiplatelet Agents in Peripheral Arterial Interventions.Seminars in interventional radiology · 2022Review
- Bleeding Complications in Patients Undergoing Percutaneous Coronary Intervention.Reviews in cardiovascular medicine · 2022Review
- Antiplatelet therapy after percutaneous coronary intervention.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2022Article
- Bleeding avoidance strategies in percutaneous coronary intervention.Nature reviews. Cardiology · 2022Review
- Current and Novel Antiplatelet Therapies for the Treatment of Cardiovascular Diseases.International journal of molecular sciences · 2021Review
- Antithrombotic and anticoagulation therapies in cardiogenic shock: a critical review of the published literature.ESC heart failure · 2021Review
- Cangrelor: Clinical Data, Contemporary Use, and Future Perspectives.Journal of the American Heart Association · 2021Review
- Coronavirus Disease 2019-Associated Thrombosis and Coagulopathy: Review of the Pathophysiological Characteristics and Implications for Antithrombotic Management.Journal of the American Heart Association · 2021Review
- Non-cardiac surgery in patients with coronary artery disease: risk evaluation and periprocedural management.Nature reviews. Cardiology · 2021Review
Corrections and comments
- Commented on by
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral antiplatelet drugs are crucially important for patients with acute coronary syndrome or stable coronary artery disease undergoing percutaneous coronary intervention (PCI). In recent decades, several clinical trials have focused on reducing periprocedural ischemic events in patients undergoing PCI by means of more rapid platelet inhibition with the use of intravenous antiplatelet drugs. Glycoprotein IIb/IIIa receptor inhibitors (GPIs) block the final common pathway of platelet aggregation and enable potent inhibition in the peri-PCI period. In recent years, however, the use of GPIs has decreased due to bleeding concerns and the availability of more potent oral P2Y
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.